Entries by Joachim Eeckhout

Boehringer steps back from MASH programm as OSE restructure its pipeline

French biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting the liver-disease leg of a separate collaboration following a mid-stage failure. The company now says it will concentrate resources on its cancer vaccine Tedopi and its IL-7 receptor antibody lusvertikimab, while pausing or ending several earlier-stage efforts to conserve cash and push toward near-term clinical catalysts.   

From cell therapy to combat rifles: Genenta bets its future on becoming Italy’s national-security dealmaker

Few biotech pivots are as jarring as Genenta’s latest move.

The Milan-based company, which went public in late 2021 on the promise of a novel cell-based gene therapy platform, is now effectively abandoning the single-asset biotech playbook. Instead, it wants to become something far closer to a holding company for defense, aerospace, cybersecurity, and national-security assets, starting with a manufacturer of tactical rifles.

,

SFDA vs EMA: What Biotech Leaders need to Know

As the regulatory strategy becomes a boardroom-level concern for biotech executives pursuing global expansion, knowing how the Saudi Food and Drug Authority (SFDA) and the European Medicines Agency (EMA) differ is crucial, particularly as Saudi Arabia accelerates its ambition to become a global life sciences hub. Although both regulators adhere to international norms, their differences in review speed, procedural flexibility, and strategic positioning can have a direct impact on competitive advantage, investment planning, and time to market.